Table 2.
Demographics and Clinical/Laboratory Characterization of Study Subjects by Postvaccination Responses: Group A versus Group BC (Inadequate Baseline-pPA vs Adequate Baseline-pPA).
| Group A: Adequate Baseline-pPA | Group BC: Inadequate Baseline-pPA | P value | |
|---|---|---|---|
| Patient cohort (%) | 58 (24) | 255 (76) | |
| Median age | 31 | 37 | .80 |
| Ethnicity (white /other) | 51/7 | 217/38 | .58 |
| Male/female | 15/43 | 96/159 | .09 |
| Recurrent infection (%) | 43 (74) | 198 (78) | .57 |
| No infection (%) | 15 (26) | 47 (22) | .35 |
| Chronic rhinosinusitis (%) | 15 (26) | 128 (50) | .001 |
| Recurrent acute sinusitis (%) | 12(21) | 49 (19) | .80 |
| Recurrent upper respiratory infection (%) | 20(34) | 40 (16) | .001 |
| Allergy sensitization (%) | 29(50) | 165 (65) | .04 |
| Asthma (%) | 25(43) | 109 (43) | .96 |
| Allergic asthma (%) | 13 (22) | 87 (34) | .08 |
| Rhinitis (allergic and nonallergic) (%) | 43 (74) | 199 (78) | .52 |
| Allergic rhinitis (%) | 26 (45) | 151 (59) | .04 |
Abbreviation: pPA, percentage of protective (≥1.3 µg/mL) pneumococcal antibody serotypes/total tested serotypes.Note: Bold values indicate statistical significance.